Anatomical pathology

Outlook on the Severe Toxicities in Lymphoma Global Industry to 2030 - Insight, Epidemiology and Market Forecast - ResearchAndMarkets.com

Tuesday, March 2, 2021 - 12:49pm

The "Severe Toxicities in Lymphoma - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Severe Toxicities in Lymphoma - Market Insight, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Severe Toxicities in Lymphoma market report provides current treatment practices, emerging drugs, Severe Toxicities in Lymphoma market share of the individual therapies, current and forecasted Severe Toxicities in Lymphoma market size from 2018 to 2030 segmented by seven major markets.
  • The Severe Toxicities in Lymphoma epidemiology division provides the insights about historical and current Severe Toxicities in Lymphoma patient pool and forecasted trend for each seven major countries.
  • To understand the future market competition in the Severe Toxicities in Lymphoma market and Insightful review of the key market drivers and barriers.

OneLegacy And Specialist Direct Partner To Save Lives

Thursday, February 25, 2021 - 7:15pm

Specialist Direct's innovative OPO solution enables OneLegacy to have access to expediated pathology interpretations by Board-Certified pathologists and subspecialists.

Key Points: 
  • Specialist Direct's innovative OPO solution enables OneLegacy to have access to expediated pathology interpretations by Board-Certified pathologists and subspecialists.
  • We are thrilled to partner with Specialist Direct to further our mission of saving and healing lives," said Prasad Garimella, Chief Operating Officer and Chief Information Officer of OneLegacy.
  • "Specialist Direct is proud to have the opportunity to collaborate with OneLegacy in providing unique diagnostic solutions to further enhance their organ recovery capabilities.
  • With Specialist Direct, OneLegacy receives fast and accurate liver and kidney biopsy interpretations, which has significantly improved its overall organ recovery process.

SHEPHERD Therapeutics and Mayo Clinic Announce Collaboration to Advance Research in Rhabdomyosarcoma Using SHEPHERD's Precision-Oncology Platform, DELVE

Thursday, February 25, 2021 - 6:03pm

BOSTON, Feb. 25, 2021 /PRNewswire/ -- SHEPHERD Therapeutics , a company dedicated to catalyzing lifesaving treatments for rare cancer patients, today announced a collaboration with the Mayo Clinic to advance research in rhabdomyosarcoma (RMS), a rare pediatric cancer with few treatment options.

Key Points: 
  • BOSTON, Feb. 25, 2021 /PRNewswire/ -- SHEPHERD Therapeutics , a company dedicated to catalyzing lifesaving treatments for rare cancer patients, today announced a collaboration with the Mayo Clinic to advance research in rhabdomyosarcoma (RMS), a rare pediatric cancer with few treatment options.
  • Our collaboration with SHEPHERD Therapeutics and access to the DELVE platform represents a unique opportunity to extrapolate from more heavily-studied cancers and accelerate rhabdomyosarcoma research.
  • The SHEPHERD Foundation is a non-profit fighting to generate industry-wide change related to rare cancer awareness and therapeutic availability.
  • DELVE is SHEPHERD's next-generation, precision-oncology platform that integrates bioinformatics, machine learning, and mathematics to unveil unprecedented insights into cancer.

Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Wednesday, February 24, 2021 - 12:00pm

The second arm will enroll up to 30 patients with Ewing-related sarcomas and will investigate seclidemstat as a single-agent therapy at the RP2D.

Key Points: 
  • The second arm will enroll up to 30 patients with Ewing-related sarcomas and will investigate seclidemstat as a single-agent therapy at the RP2D.
  • Nadeem Q. Mirza, M.D., M.P.H., Senior Vice President, Clinical Development for Salarius, commented, There is strong support for this development strategy.
  • Dr. Mirza continued, The expansion into Ewing-related sarcomas is supported by encouraging signs of seclidemstat clinical activity among the subset of Ewing-related sarcoma patients enrolled in our Advanced Solid Tumor trial.
  • ET, to discuss advancements in the Phase 1/2 clinical trial of seclidemstat in patients with Ewing sarcoma and Ewing-related sarcomas.

Latest Association for Molecular Pathology Survey Findings Indicate Significant Decline in Molecular Testing for Cancer During COVID-19 Pandemic

Tuesday, February 23, 2021 - 6:39pm

ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its " Molecular Testing for Cancer during COVID-19 " survey of clinical laboratories.

Key Points: 
  • ROCKVILLE, Md., Feb. 23, 2021 /PRNewswire/ --The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its " Molecular Testing for Cancer during COVID-19 " survey of clinical laboratories.
  • The latest anonymous survey assessed how important components of molecular diagnostic testing for cancer, including testing volumes, laboratory operations, clinical trial testing, patient samples, and turnaround times, were affected by the COVID-19 pandemic.
  • Overall, 85% of respondents reported that molecular testing for cancer decreased during April-June 2020.
  • The results from this survey underscore the significant supply chain and staffing shortages that were reported in AMP's April and August SARS-CoV-2 molecular testing surveys and show that they reverberate to molecular diagnostic testing for cancer.

New Book Fills Gap in Currently Available Pathology Texts

Monday, February 22, 2021 - 12:15pm

Surgical Pathology Review helps to round out the pathologist into a fully developed diagnostician and to successfully prepare for certification examinations.

Key Points: 
  • Surgical Pathology Review helps to round out the pathologist into a fully developed diagnostician and to successfully prepare for certification examinations.
  • It is meant to complement currently available pathology texts, bridging the chasm between larger textbooks concerned with the practical aspects of histopathologic diagnosis and basic texts focused on conceptual fundamentals of pathology.
  • The book is organized by organ system with specific lesions found, explains Dr. Mais.
  • With more than 2,000 images, the 488-page book is available in softcover ($100 for CAP members, $125 for others) and ebook ($95) formats.

New Digital Pathology Report from Hamamatsu Reveals that a Changing Environment is Accelerating Adoption of Digital Solutions

Wednesday, February 17, 2021 - 4:00pm

HAMAMATSU, Japan., Feb. 17, 2021 /PRNewswire/ --Hamamatsu Photonics K.K.,a leading international provider of photonics devices, today published a new market report on perceptions and utilization of digital pathology solutions, At the Tipping Point .

Key Points: 
  • HAMAMATSU, Japan., Feb. 17, 2021 /PRNewswire/ --Hamamatsu Photonics K.K.,a leading international provider of photonics devices, today published a new market report on perceptions and utilization of digital pathology solutions, At the Tipping Point .
  • With findings from a survey of pathologists, laboratory directors, and hospital leaders across the U.S., the report reveals that most see value in digital pathology.
  • "Technology has always been a part of bleeding-edge healthcare, but pathology is an area where digital imaging innovation has been slow to catch on," said Don Ariyakumar, Hamamatsu's product manager for whole slide imaging and digital pathology.
  • "Using glass slides is reliable, but slow and inefficient, and a lack of superior digital solutions, along with a lack of FDA-cleared systems, for years made pathologists hesitant to adopt digitization.

Natera and Personalis Partner for Personalized Monitoring in Oncology

Wednesday, February 17, 2021 - 2:01pm

The partnership will pair Personalis NeXT tumor profiling and diagnostic products with Nateras personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease (MRD) assessment.

Key Points: 
  • The partnership will pair Personalis NeXT tumor profiling and diagnostic products with Nateras personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease (MRD) assessment.
  • Under this non-exclusive agreement, Natera will validate the design of Signatera personalized ctDNA assays using matched tumor and normal exome sequence data from Personalis, and Natera will be responsible for commercialization.
  • We are pleased to partner with them and to expand access of Signatera to a new set of potential customers.
  • We are excited to partner with Natera on this sensitive tumor-informed approach to accelerate molecular residual disease detection in cancer.

Salarius Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Wednesday, February 17, 2021 - 12:30pm

The Phase 1/2 clinical trial of seclidemstat in patients with Ewing sarcoma was designed as an open-label, multi-center, dose-finding study.

Key Points: 
  • The Phase 1/2 clinical trial of seclidemstat in patients with Ewing sarcoma was designed as an open-label, multi-center, dose-finding study.
  • Data from patients treated in the dose-escalation portion of the trial demonstrated seclidemstat had a manageable safety profile.
  • In addition to treating R/R Ewing sarcoma patients, the expansion portion of the Phase 1/2 trial will enroll patients with additional select sarcomas that share a similar biology to Ewing sarcoma.
  • The decision to include Ewing-related sarcoma patients was supported by preclinical data and encouraging clinical data in Salarius AST trial.

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia

Wednesday, February 17, 2021 - 12:00pm

We are pleased that the FDA has accepted the sNDA for BRUKINSA in WM, a rare disease with significant morbidity.

Key Points: 
  • We are pleased that the FDA has accepted the sNDA for BRUKINSA in WM, a rare disease with significant morbidity.
  • In addition, safety data from 779 patients in six clinical trials of BRUKINSA were included in the submission.
  • Waldenstrms macroglobulinemia (WM) is a rare indolent B-cell lymphoma that occurs in less than two percent of patients with non-Hodgkins lymphoma (NHL).
  • A supplemental new drug application (sNDA) of BRUKINSA in patients with Waldenstrms macroglobulinemia (WM) has been accepted for review by the FDA.